


Anti-AR antibody



Description	Rabbit polyclonal to AR.
Model	STJ91659
Host	Rabbit
Reactivity	Human
Applications	ELISA, IHC, WB
Immunogen	Synthesized peptide derived from human AR around the non-phosphorylation site of S650.
Immunogen Region	590-670 aa
Gene ID	367
Gene Symbol	AR
Dilution range	WB 1:500-1:2000IHC 1:100-1:300ELISA 1:40000
Specificity	AR Polyclonal Antibody detects endogenous levels of AR protein.
Tissue Specificity	Isoform 2 is mainly expressed in heart and skeletal muscle . Isoform 3 is expressed by basal and stromal cells of prostate (at protein level) .
Purification	The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Note	For Research Use Only (RUO).
Protein Name	Androgen receptor Dihydrotestosterone receptor Nuclear receptor subfamily 3 group C member 4
Molecular Weight	110/99 kDa

Clonality	Polyclonal
Conjugation	Unconjugated
Isotype	IgG
Formulation	Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Concentration	1 mg/ml
Storage Instruction	Store at -20°C, and avoid repeat freeze-thaw cycles.
Database Links	HGNC:644OMIM:300068
Alternative Names	Androgen receptor Dihydrotestosterone receptor Nuclear receptor subfamily 3 group C member 4
Function	Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription factor activity is modulated by bound coactivator and corepressor proteins. Transcription activation is down-regulated by NR0B2. Activated, but not phosphorylated, by HIPK3 and ZIPK/DAPK3. Isoform 3 and isoform 4 lack the C-terminal ligand-binding domain and may therefore constitutively activate the transcription of a specific set of genes independently of steroid hormones.
Sequence and Domain Family	Composed of three domains: a modulating N-terminal domain, a DNA-binding domain and a C-terminal ligand-binding domain. In the presence of bound steroid the ligand-binding domain interacts with the N-terminal modulating domain, and thereby activates AR transcription factor activity. Agonist binding is required for dimerization and binding to target DNA. The transcription factor activity of the complex formed by ligand-activated AR and DNA is modulated by interactions with coactivator and corepressor proteins. Interaction with RANBP9 is mediated by both the N-terminal domain and the DNA-binding domain. Interaction with EFCAB6/DJBP is mediated by the DNA-binding domain.
Cellular Localization	Nucleus Cytoplasm. Predominantly cytoplasmic in unligated form but translocates to the nucleus upon ligand-binding. Can also translocate to the nucleus in unligated form in the presence of RACK1.
Post-translational Modifications	Sumoylated on Lys-388 (major) and Lys-521. Ubiquitinated. Deubiquitinated by USP26. 'Lys-6' and 'Lys-27'-linked polyubiquitination by RNF6 modulates AR transcriptional activity and specificity. Phosphorylated in prostate cancer cells in response to several growth factors including EGF. Phosphorylation is induced by c-Src kinase (CSK). Tyr-535 is one of the major phosphorylation sites and an increase in phosphorylation and Src kinase activity is associated with prostate cancer progression. Phosphorylation by TNK2 enhances the DNA-binding and transcriptional activity and may be responsible for androgen-independent progression of prostate cancer. Phosphorylation at Ser-83 by CDK9 regulates AR promoter selectivity and cell growth. Phosphorylation by PAK6 leads to AR-mediated transcription inhibition. Palmitoylated by ZDHHC7 and ZDHHC21. Palmitoylation is required for plasma membrane targeting and for rapid intracellular signaling via ERK and AKT kinases and cAMP generation.

St John's Laboratory Ltd

F +44 (0)207 681 2580

T +44 (0)208 223 3081

W <http://www.stjohnslabs.com/>

E info@stjohnslabs.com